Skip to Content

Clinical Trials

Last Updated: 7/1/2014

Leukemia Clinical Trials are Grouped by Disease Type:

Phase I Agents

Acute Lymphoblastic Leukemia (ALL)

Newly Diagnosed or Previously Treated 

Salvage Programs

Acute Myelogenous Leukemia (AML)

Newly Diagnosed

FLT3 Mutated Only

Frontline AML Post-Hypomethylating Therapy for MDS

Secondary Leukemia

Salvage

Supportive Care for AML

Maintenance (Patients in CR)

  • Oral AZA + BSC vs BSC as maintenance in AML in CR (2012-0866)

Myelodysplastic Syndrome (MDS) (Includes CMML)

Specific Situations

  • Hypoplastic MDS and aplastic anemia - Horse ATG (2012-0334)
  • MDS/MPN - Ruxolitinib + AZA (2012-0737)
  • FLT3Positive - AC220 + 5-AZA or LD Ara-C (2012-1047)
  • FLT3Positive - Crenolanib (2012-0569)

RAS Mutated

Post Hypomethylating Agents:

Low Risk/IPSS Int-1

IPSS int-2 or high

MDS 20% Blasts

Chronic Lymphocytic Leukemia (CLL)

CLL Immunotherapy

Untreated - early stage

Untreated - all stages 

Mimimal Residual Disease

Prior Therapy

  • Ibrutinib vs Ibrutinib+Rituximab (2013-0703)
  • Ublituximab + TGR-1202 (2013-0566)
  • ACP-196 (2013-0907)
  • ABT-199 (2013-0315)
  • ABT-199 (2011-0164)
  • Sapacitabine + Cyclophosphamide + Rituximab (2010-0516)
  • TRU-016 + Rituximab (2012-0626)                                                             
  • Fludarabine + bendamustine + rituximab (2009-0546)

Other Studies

Chronic Myelogenous Leukemia (CML)

Chronic phase

Accelerated Phase

Blastic Phase

Minimal Residual Disease

Treatment Discontinuation

  • Dasatinib Therapy Discontinuation (2013-0629)

Supportive Care

Other Studies

Roll-over Studies

Myeloproliferative Diseases

MDS/MPD

Leukemia Insights

Leukemia Insights is a quarterly newsletter for physicians and other health professionals. Insights has the latest leukemia news, research and results from ongoing clinical trials, and available leukemia programs at MD Anderson.


© 2014 The University of Texas MD Anderson Cancer Center